CureVac Sees Unusually High Options Volume (NASDAQ:CVAC)

CureVac (NASDAQ:CVAC) was the recipient of some unusual options trading on Thursday. Stock investors purchased 1,936 call options on the stock. This is an increase of 849% compared to the average volume of 204 call options.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. JMP Securities reissued a “market outperform” rating and issued a $10.00 price target on shares of CureVac in a research note on Wednesday, May 28th. UBS Group dropped their price target on CureVac from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Wednesday, April 30th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $5.00 price target (down from $7.00) on shares of CureVac in a research note on Friday.

Institutional Investors Weigh In On CureVac

Several hedge funds and other institutional investors have recently modified their holdings of CVAC. Greenleaf Trust bought a new stake in CureVac during the first quarter worth $31,000. Integrated Wealth Concepts LLC grew its holdings in CureVac by 25.0% during the first quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock worth $42,000 after buying an additional 3,000 shares in the last quarter. Two Sigma Advisers LP bought a new stake in CureVac during the fourth quarter worth $48,000. Jump Financial LLC bought a new stake in CureVac during the fourth quarter worth $55,000. Finally, D. E. Shaw & Co. Inc. bought a new stake in CureVac during the fourth quarter worth $66,000. Institutional investors own 17.26% of the company’s stock.

CureVac Trading Down 0.5%

NASDAQ CVAC opened at $5.57 on Friday. The company has a market cap of $1.25 billion, a price-to-earnings ratio of 10.13 and a beta of 2.49. CureVac has a 52 week low of $2.37 and a 52 week high of $5.72. The business has a 50 day moving average price of $3.76 and a 200-day moving average price of $3.48. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05.

CureVac (NASDAQ:CVAC) last released its quarterly earnings data on Thursday, May 22nd. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.08). The firm had revenue of $0.94 million for the quarter, compared to the consensus estimate of $4.27 million. CureVac had a net margin of 20.72% and a return on equity of 21.98%. As a group, equities analysts expect that CureVac will post 0.72 earnings per share for the current fiscal year.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.